Esomeprazole + Lansoprazole

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Erosive Esophagitis

Conditions

Erosive Esophagitis

Trial Timeline

Dec 1, 2002 → Jan 1, 2004

NCT ID

NCT00644735

About Esomeprazole + Lansoprazole

Esomeprazole + Lansoprazole is a approved stage product being developed by AstraZeneca for Erosive Esophagitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00644735. Target conditions include Erosive Esophagitis.

What happened to similar drugs?

5 of 12 similar drugs in Erosive Esophagitis were approved

Approved (5) Terminated (0) Active (7)

✅Teprenone capsule and placebo of sucralfate + Sucralfate and placebo of teprenoneEisaiApproved

✅Esomeprazole + LansoprazoleAstraZenecaApproved

✅Esomeprazole + EsomeprazoleAstraZenecaApproved

✅esomeprazole magnesium (oral medication)AstraZenecaApproved

✅Omeprazole/sodium bicarbonateBausch HealthApproved

🔄E3810 + E3810 + PlaceboEisaiPhase 3

🔄RABEPRAZOLE SODIUM + RABEPRAZOLE SODIUMEisaiPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00352261	Approved	Completed	Jan 1, 2006	Apr 1, 2007	Barrett's Esophagus
NCT00644735	Approved	Completed	Dec 1, 2002	Jan 1, 2004	Erosive Esophagitis
NCT00641602	Approved	Completed	Dec 1, 2002	Aug 1, 2003	Erosive Esophagitis

Competing Products

20 competing products in Erosive Esophagitis

See all competitors

Product	Company	Stage	Hype Score
YH1885L(Revaprazan) + Esomeprazole 20mg + placebo	Yuhan	Phase 2	35
E3810 + E3810 + Placebo	Eisai	Phase 3	40
RABEPRAZOLE SODIUM + RABEPRAZOLE SODIUM	Eisai	Phase 3	40
Teprenone capsule and placebo of sucralfate + Sucralfate and placebo of teprenone	Eisai	Approved	43
ABT-981 + Placebo for ABT-981	AbbVie	Phase 2	35
Omeprazole	AstraZeneca	Phase 3	40
Nexium 20mg + Nexium 10mg	AstraZeneca	Phase 3	47
Omeprazole	AstraZeneca	Phase 3	40
AZD0865	AstraZeneca	Phase 2	35
Esomeprazole + Lansoprazole	AstraZeneca	Approved	43
Esomeprazole + Esomeprazole	AstraZeneca	Approved	43
AZD0865	AstraZeneca	Phase 2	35
esomeprazole magnesium (oral medication)	AstraZeneca	Approved	43
Alendronate Effervescent Oral Tablet	Amgen	Phase 2	35
Omeprazole/sodium bicarbonate	Bausch Health	Approved	37
Vonoprazan	Phathom Pharmaceuticals	Phase 1	23
Vonoprazan + Lansoprazole	Phathom Pharmaceuticals	Phase 3	34
Vonoprazan + Placebo	Phathom Pharmaceuticals	Phase 2	29
Vonoprazan	Phathom Pharmaceuticals	Pre-clinical	27
Vonoprazan + Placebo	Phathom Pharmaceuticals	Phase 3	34